Near-infrared laser adjuvant for influenza vaccine

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kashiwagi, Satoshi ^a   Yuan, Jianping ^a   Forbes, Benjamin ^a   Hibert, Mathew L ^a   Lee, Eugene L Q ^a   Whicher, Laura ^a   Goudie, Calum ^a   Yang, Yuan ^a   Chen, Tao ^a   Edelblute, Beth ^a   Collette, Brian ^a   Edington, Laurel ^a   Trussler, James ^a   Nezivar, Jean ^a   Leblanc, Pierre ^a   Bronson, Roderick ^b   Tsukada, Kosuke ^c   Suematsu, Makoto ^c   Dover, Jeffrey ^d   Brauns, Timothy ^a   Gelfand, Jeffrey ^a   Poznansky, Mark C ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KEIO UNIVERSITY   (Japan)

^d SkinCare Physicians of Chestnut Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN E; INFLUENZA VACCINE; NEODYMIUM; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFRARED RADIATION; INNATE IMMUNITY; LASER SAFETY; LOW LEVEL LASER THERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MIDDLE AGED; MOUSE; NEODYMIUM DOPED YTTRIUM ORTHVANADATE LASER; NONHUMAN; NORMAL HUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; SKIN DEFECT; SKIN SENSATION; SKIN TEMPERATURE; SOLID STATE LASER; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT; ANIMAL; DEVICES; IMMUNOLOGY; INFLUENZA VIRUS A; LASER; ORTHOMYXOVIRIDAE INFECTIONS; PROCEDURES; SKIN; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFRARED RAYS; LASERS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SKIN; VACCINATION;

EID: 84892406414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082899     Document Type: Article

References (67)

1. Leroux-Roels G (2010) Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3: C25-36.
2. Harandi AM, Davies G, Olesen OF (2009) Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 8: 293-298.
3. Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11: 865-872.
4. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, et al. (2010) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/ Centers for Disease Control 59: 1-62.
5. Lambert LC, Fauci AS (2010) Influenza vaccines for the future. N Engl J Med 363: 2036-2044.
6. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet infectious diseases 12: 36-44.
7. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357: 1373-1381.
8. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356: 685-696.
9. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
10. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
11. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, et al. (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43: 1135-1142.
12. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/ Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
13. Vogel FR, Caillet C, Kusters IC, Haensler J (2009) Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 8: 483-492.
14. Batista-Duharte A, Lindblad EB, Oviedo-Orta E (2011) Progress in understanding adjuvant immunotoxicity mechanisms. Toxicology letters 203: 97-105.
15. Gupta RK, Rost BE, Relyveld E, Siber GR (1995) Adjuvant properties of aluminum and calcium compounds. Pharmaceutical biotechnology 6: 229-248.
16. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, et al. (2009) Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27: 5091-5095.
17. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197: 667-675.
18. Sticchi L, Alberti M, Alicino C, Crovari P (2010) The intradermal vaccination: past experiences and current perspectives. J Prev Med Hyg 51: 7-14.
19. Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, et al. (2011) Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 89: 221-226.
20. Lambert PH, Laurent PE (2008) Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26: 3197-3208.
21. Atmar RL, Patel SM, Keitel WA (2010) Intanza((R)): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 9: 1399-1409.
22. Ansaldi F, de Florentiis D, Durando P, Icardi G (2012) Fluzone((R)) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 11: 17-25.
23. Young F, Marra F (2011) A systematic review of intradermal influenza vaccines. Vaccine 29: 8788-8801.
24. Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX (2012) High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31: 159-164.
25. Chen X, Kim P, Farinelli B, Doukas A, Yun SH, et al. (2010) A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS ONE 5: e13776.
26. Onikienko SB, Zemlyanoy AB, Margulis BA, Guzhova IV, Varlashova MB, et al. (2007) Diagnostics and correction of the metabolic and immune disorders. Interactions of bacterial endotoxins and lipophilic xenobiotics with receptors associated with innate immunity. Donosologiya (St Petersburg) 1: 32-54.
27. Boulnois J-L (1986) Photophysical processes in recent medical laser developments: A review. Lasers in Medical Science 1: 47-66.
28. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, et al. (2009) Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 4: e4773.
29. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, et al. (2009) Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27: 6932-6938.
30. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, et al. (2010) Dissolving polymer microneedle patches for influenza vaccination. Nat Med 16: 915-920.
31. Quan FS, Kim YC, Vunnava A, Yoo DG, Song JM, et al. (2010) Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 84: 7760-7769.
32. Frey A, Di Canzio J, Zurakowski D (1998) A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 221: 35-41.
33. Matsuoka Y, Lamirande EW, Subbarao K (2009) The mouse model for influenza. Curr Protoc Microbiol Chapter 15: Unit 15G 13.
34. Szretter KJ, Balish AL, Katz JM (2006) Influenza: propagation, quantification, and storage. Curr Protoc Microbiol Chapter 15: Unit 15G 11.
35. Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, et al. (2004) Visualizing dendritic cell networks in vivo. Nat Immunol 5: 1243-1250.
36. Ng LG, Hsu A, Mandell MA, Roediger B, Hoeller C, et al. (2008) Migratory dermal dendritic cells act as rapid sensors of protozoan parasites. PLoS Pathog 4: e1000222.
37. Fitzpatrick TB (1988) The validity and practicality of sun-reactive skin types I through VI. Archives of dermatology 124: 869-871.
38. Niemz MH (2007) Laser-Tissue Interactions: Fundamentals and Applications (Biological and Medical Physics, Biomedical Engineering) Springer. 308 p.
39. Hauge S, Madhun A, Cox RJ, Haaheim LR (2007) Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies. Clin Vaccine Immunol 14: 978-983.
40. Vilanova M, Teixeira L, Caramalho I, Torrado E, Marques A, et al. (2004) Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 111: 334-342.
41. Morefield GL, Tammariello RF, Purcell BK, Worsham PL, Chapman J, et al. (2008) An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J Immune Based Ther Vaccines 6: 5.
42. Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES (2010) Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication. Vaccine 28: 5315-5322.
43. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, et al. (2000) Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31: 521-527.
44. Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, et al. (2009) Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 28: 171-178.
45. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ (2009) Skin immune sentinels in health and disease. Nat Rev Immunol 9: 679-691.
46. Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7: 543-555.
47. Guebre-Xabier M, Hammond SA, Epperson DE, Yu J, Ellingsworth L, et al. (2003) Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J Virol 77: 5218-5225.
48. Alvarez D, Vollmann EH, von Andrian UH (2008) Mechanisms and consequences of dendritic cell migration. Immunity 29: 325-342.
49. Swain SL, McKinstry KK, Strutt TM (2012) Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol 12: 136-148.
50. Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerging infectious diseases 12: 48-54.
51. England RW, Vogel P, Hagan L (2002) Immediate cutaneous hypersensitivity after treatment of tattoo with Nd:YAG laser: a case report and review of the literature. Annals of allergy, asthma & immunology 89: 215-217.
52. Ashinoff R, Levine VJ, Soter NA (1995) Allergic reactions to tattoo pigment after laser treatment. Dermatologic surgery 21: 291-294.
53. Sliney DH, Palmisano WA (1968) The evaluation of laser hazards. Am Ind Hyg Assoc J 29: 425-431.
54. Vitoriano-Souza J, Moreira N, Teixeira-Carvalho A, Carneiro CM, Siqueira FA, et al. (2012) Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A. PLoS ONE 7: e40745.
55. Furuya Y (2011) Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol.
56. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13: 981-990.
57. Hovden AO, Cox RJ, Haaheim LR (2005) Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol 62: 36-44.
58. Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, et al. (2008) Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26: 2350-2359.
59. Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809.
60. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
61. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
62. Belyakov IM, Ahlers JD (2009) What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 183: 6883-6892.
63. Palladino G, Mozdzanowska K, Washko G, Gerhard W (1995) Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69: 2075-2081.
64. Martin-Fontecha A, Lanzavecchia A, Sallusto F (2009) Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol: 31-49.
65. Platt AM, Randolph GJ (2013) Dendritic cell migration through the lymphatic vasculature to lymph nodes. Adv Immunol 120: 51-68.
66. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK (2009) Microneedle-based vaccines. Curr Top Microbiol Immunol 333: 369-393.
67. Karande P, Mitragotri S (2010) Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol Eng 1: 175-201.